

DAFTAR PUSTAKA

1. Dipiro JT, Yee GC, Haines ST, Nolin TD, Ellingrod VL, Posey LM. *DiPiro's Pharmacotherapy A Pathophysiologi Approach*. New York: Mc Graw Hill; 2016. 1–23 .
2. Kemenkes RI. Laporan Riskesdas 2018 Nasional. Lembaga Penerbit Balitbangkes. 2020. p. 70–75.
3. Schwinghammer TL, DiPiro JT, Ellingrod VL, DiPiro C V. *Pharmacotherapy handbook*. Mc Graw-Hill. New York; 2021. 749–759 p.
4. Hanna A zahra I, Hasmono D, Issaura, Syifa N. Studi Penggunaan Antidislipidemia Pada Pasien Stroke Iskemik (Penelitian dilakukan di RSUD R . T . Notopuro Sidoarjo). *Indones J Pharm Educ*. 2024;4(3):450–60.
5. Latif WD, Aswad M, Bahar MA. Perbandingan Efektivitas Klinik Simvastatin dan Atorvastatin Terhadap Profil Lipid Darah: Studi Kasus di Rumah Sakit Universitas Hasanuddin. *J Sains Farm Klin*. 2022;9(1):34–41.
6. Pane MH, Rahman AO, Ayudia EI. Gambaran Penggunaan Obat Herbal pada Masyarakat Indonesia dan Interaksinya terhadap Obat Konvensional. *J Med Stud*. 2021;1(1):40–62.
7. Husnayanti A, Zahriah. Pola Penggunaan Obat Herbal sebagai Terapi Komplementer pada Pasien Hiperkolesterol di Puskesmas Kota Pangkalpinang Tahun 2020. *J Kesehat Poltekkes Kemenkes RI Pangkalpinang*. 2021;9(1):25–36.
8. Dewi RS, Wahyuni, Pratiwi E, Muharni S. Penggunaan Obat Tradisional Oleh Masyarakat di Kelurahan Tuah Karya Kota Pekanbaru. *J Penelit Farm Indones*. 2019;8(1):41–5.
9. Dianita R, Jubahar J, Dachriyanus. Isolation of Antioxidant Compounds from The Stem Bark *Garcinia Cowa*. *J Math Nat Sci*. 2003;12:67–72.
10. H.Y. JEM, Christy Muliono A. Berbagai Faktor yang Berkontribusi Terhadap Kejadian Statin-Associated Muscle Symptoms Imbas Atorvastatin. Vol. 23, *Damianus Journal of Medicine*. 2024.
11. Talele GS, Porwal PK. Development of Validated Bioanalytical HPLC-UV Method for Simultaneous Estimation of Amlodipine and Atorvastatin in Rat Plasma. *Indian J Pharm Sci*. 2015;77(6):742–50.
12. Dachriyanus, Asjar NS, Susanti M. Determination of rubraxanthone in the latex of asam kandis (*Garcinia cowa Roxb*) by reverse phase high performance liquid chromatography. *Pharmacogn J*. 2017;9(2):288–91.
13. Susanti M, Darmianti R, Harahap Y, Itam A, Hamidi D. Single dose oral pharmacokinetic profile rubraxanthone in mice. *Heliyon*. 2022;8(3).
14. Putri Eka Diah Lestari, Aulia Khajar Raudhatul Jannah, Hasna' Khoirotun

- Hisan, Maoliani Nurul Fitri, Nessa Aulia Azharani. Analisis Perbandingan HPLC dan Teknik Lain untuk Deteksi Antibiotik. *Termom J Ilm Ilmu Kesehatan dan Kedokt.* 2023;2(2):01–11.
15. Zakaria R, Allen KJ, Koplin JJ, Roche P, Greaves RF. Advantages and Challenges of Dried Blood Spot Analysis by Mass Spectrometry Across the Total Testing Process. *eJIFC.* 2016;27(4):288–317.
 16. Supandi. Prospektif Metode sampel Darah Kering dalam Bioanalisis. *J Trop Pharm Chem.* 2016;3(3):224–31.
 17. Lee MS, Li W. *Dried Blood Spots : Applications and Techniques.* USA: Wiley; 2014. 363 p.
 18. Alkadi KAA, Adam A, M T, Hasan M, Shah SAA. Prenylated Xanthone and Rubraxanthone with Antiplatelet Aggregation Activity in Human Whole Blood Isolated from *Garcinia griffithii*. *Orient J Chem.* 2013;29:1291–5.
 19. Pattalung PN, Wiriyachitra P, Oongsakul M. The Antimicrobial Activities of Rubraxanthone Isolated from *Garcinia parvifolia* (Miq.) Miq. *J. Sci. Soc. Thailand* 14. 1988. p. 67–71.
 20. Wahyuni FS, Byrne LT, Dachriyanus, Dianita R, Jubahar J, Lajis NH, et al. A New Ring-Reduced Tetraprenyltoluquinone and a Prenylated Xanthone from *Garcinia cowa*. *Aust J Chem.* 2004;57(3):223–6.
 21. G. C. L. E, Foo CH, Jong VYM, Ismail NH, Sukari MA, Yap YHT. A New Xanthone from *Garcinia nitida*. *Nat Prod Res Former Nat Prod Lett.* 2014;26(9):37–41.
 22. Susanti M. Pengujian Profil Farmakokinetika Rubrasanton Yang Diisolasi Dari Kulit Batang Asam Kandis (*Garcinia cowa* Roxb) Setelah Pemberian Secara Oral Pada Mencit. Universitas Andalas; 2019.
 23. PubChem. National Center for Biotechnology Information. 2025 [cited 2025 Oct 6]. Rubraxanthone. Available from: <https://pubchem.ncbi.nlm.nih.gov/compound/9953366>
 24. Wahyuni FS, Shaari K, Stanslas J, Lajis NH. Research Article Cytotoxic xanthenes from the stem bark of *Garcinia cowa* Roxb OMe 5a O. *J Chem Pharm Res.* 2015;7(1):227–36.
 25. Alen Y, Safitri N, Dachriyanus, Ali AM, Ladjis NH, Sargent M V. Rubraxanthone dari *Garcinia forbesii* king dan Bioaktivitasnya. *J Ris Kim.* 2008;1(1).
 26. Iinuma M, Tosa H, Tanaka T, Asai F, Kobayashi Y, Shimano R, et al. Antibacterial Activity of Xanthenes from Guttiferaceous Plants Against Methicillin-Resistant *Staphylococcus aureus*. *J Pharm Pharmacol.* 1996;48(8):861–5.
 27. Jantan I, Pizar M, Idris MS, Taher M, Ali RM. In Vitro Inhibitory Effect of Rubraxanthone Isolated from *Garcinia parvifolia* on Platelet-Activating Factor Receptor Binding. *Planta Med.* 2002;68:1133-1134 '.

28. McDowall RD. Sample Preparation for Biomedical Analysis. *J Chromatogr B Biomed Sci Appl*. 1989;492(C):3–58.
29. Susanti M, Harahap Y, Itam A, Dachriyanus. Development and Validation of UPLC-UV Method for the Determination of Rubraxanthone in Human Plasma. *J Pharm Pharmacogn Res*. 2019;7(5):381–8.
30. Salma UK. Review Artikel: Peningkatan Kelarutan Atorvastatin Dengan Berbagai Metode Dispersi Padat. *J Ilm Farm Farmasyifa*. 2021;4(1):6–16.
31. Kemenkes. Farmakope Indonesia Edisi VI. Jakarta: Kemenkes RI; 2020.
32. PubChem. National Center for Biotechnology Information. 2025 [cited 2025 Dec 4]. Compound Summary for CID 60823, Atorvastatin. Available from: <https://pubchem.ncbi.nlm.nih.gov/compound/Atorvastatin>.
33. Azhary DP, Supriadi D, Mardhiani YD, Sinta A. Peningkatan Laju Disolusi Atorvastatin Dengan Dispersi Padat Menggunakan Pembawa Karagenan. *J Ilm Farm Farmasyifa*. 2020;3(1):44–50.
34. Udin B, Kholifah E. Literature Review: Mekanisme Kerja Obat Antidislipidemia. *J Ilm Bakti Farm*. 2023;6(1):35–44.
35. Lennernäs H. Clinical Pharmacokinetics of Atorvastatin. *Clin Pharmacokinet*. 2003;42(13):1141–60.
36. Kim S, Seo J Do, Yun YM, Kim H, Kim TE, Lee T, et al. Pharmacokinetics and Genetic Factors of Atorvastatin in Healthy Korean Subjects. *Front Genet*. 2022;13(May):1–9.
37. Zarghi A, Shafaati A, Mohsen S, Khoddam A. A Simple and Rapid HPLC Method for the Determination of Atorvastatin in Human Plasma with UV Detection and its Application to Pharmacokinetic Studies. 2005;454(8):451–4.
38. Khan IU, Jillani SMS, Ashfaq M. Determination of atorvastatin and gemfibrozil in human plasma by reversed-phase liquid chromatography. *Lat Am J Pharm*. 2010;29(8):1383–8.
39. Polagani SR, Pilli NR, Gajula R, Gandu V. Simultaneous Determination of Atorvastatin, Metformin and Glimepiride in Human Plasma by LC-MS/MS and its Application to a Human Pharmacokinetic Study. *J Pharm Anal*. 2013;3(1):9–19.
40. European Medicines Agency. European Medicines Agency. Guideline on Bioanalytical Method Validation. EMA Guid Doc. 2011;1–23.
41. Hansen SH, Bjergaard SP, Wiley J. Bioanalysis of Pharmaceuticals: Sample Preparation, Separation Techniques and Mass Spectrometry. Denmark: WILEY; 2015.
42. Ambwani S, Misra AK, Rajesh K. Prucalopride: A Recently Approved Drug by the Food and Drug Administration for Chronic Idiopathic Constipation. *Int J Appl Basic Med Res*. 2018;8(1):1–2.

43. Rosita L, Cahya AA, Arfira F, Athiya R. Buku Hematologi Dasar. Universitas Islam Indonesia. Yogyakarta; 2019. 1–122 p.
44. Rohman A. Analisis Farmasi dengan Kromatografi Cair. Yogyakarta: Gadjah Mada University Press; 2020.
45. Harmita AAK, Harahap Y, Supandi. Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS). Jakarta: isfi Penerbitan; 2019.
46. Susanti M, Dachriyanusus. Kromatografi Cair Kinerja Tinggi. Lembaga Pengembangan Teknologi Informasi dan Komunikasi (LPTIK) Universitas Andalas; 2014.
47. Taleuzzaman M, Chattopadhyay MMAM. Particle size role, Importance and Strategy of HPLC Analysis-An update. Int Arch Biomed Clin Res. 2016;2(2):5–11.
48. Rohman A. Validasi Penjaminan Mutu Metode Analisis Kimia. Yogyakarta: Gadjah Mada University Press; 2018.
49. Sukmawati, Sudewi S, Pontoh J. Optimasi dan Validasi Metode Analisis Dalam Penentuan Kandungan Total Flavonoid Pada Ekstrak Daun Gedi Hijau (*Abelmoschus manihot* L.) Yang Diukur Dengan Spektrofotometer UV-VIS. Pharmacon. 2018;7(3):32–41.
50. Hadi A. Persyaratan Umum Kompetensi Laboratorium Pengujian & Laboratorium Kalibrasi. Jakarta: Gramedia Pustaka utama; 2018.
51. Kurniawan RN, Ersam T. Isolasi Senyawa Rubrasanton dan Parvifolisanton C dari Ekstrak Kulit Batang Garcinia Tetrandra Pierre. J Sains dan Seni ITS. 2018;7(1):10–4.
52. Min H, Park J hwan, Phuoc N, Kim D duk, Won S. Simultaneous determination of cardiovascular drugs in dried blood spot by liquid chromatography-tandem mass spectrometry. J Food Drug Anal [Internet]. 2019;27(4):906–14. Available from: <https://doi.org/10.1016/j.jfda.2019.06.001>
53. Talay A, Demiralay EÇ, Doğan Daldal Y, Üstün Z. Investigation of thermodynamic acidity constants of some statins with RPLC method. J Mol Liq. 2015;208:286–90.
54. Harahap Y, Irawan H, Kuswardani. Development and validation of analytical method of 3, 4-methylenedioxy-n-ethylamphetamine in dried blood spot using gas chromatography-mass spectrometry. Int J Appl Pharm. 2020 Jul 1;12(4):94–9.
55. Yugatama A, Rohmani S, Dewangga A. Development and Validation of High Performance Liquid Chromatography Method for Determination Atorvastatin in Tablet. In: IOP Conference Series: Materials Science and Engineering. Institute of Physics Publishing; 2018.
56. Young JCOC. True Melting Point Determination. 2013;4171(13):203–8.

57. Susanti M, Lena DI, Dachriyanus D. Development and Validation of a Hplc Method for Determination and Quantification of Rubraxanthone in Stem Bark Extract of Mangosteen. *Indones J Pharm.* 2014;25(4):237.
58. Dachriyanus. Analisis Struktur Senyawa Organik Secara spektroskopi. Padang: LPTIK Universitas Andalas; 2004.
59. Tan A, Boudreau N, Lévesque A. Internal Standar for quantitative LC-MS in bioanalysis. Vol. 9781461438, LC-MS in Drug Bioanalysis. 2012. 1- p.
60. Desai AM, Andrae M, Mullena DG, Holl MMB. Acetonitrile shortage: use of isopropanol as an alternative elution system for ultra/high performance liquid chromatography. *Anal methods.* 2012;3(1):56–8.
61. Subirats X, Bosch E, Rosés M. Retention of ionisable compounds on high-performance liquid chromatography XVIII: pH variation in mobile phases containing formic acid, piperazine, tris, boric acid or carbonate as buffering systems and acetonitrile as organic modifier. *J Chromatogr A.* 2009;1216(12):2491–8.
62. Alruwaili NK. Analytical Quality by Design Approach of Reverse-Phase High-Performance Liquid Chromatography of Atorvastatin: Method Development, Optimization, Validation, and the Stability-Indicated Method. *Int J Anal Chem.* 2021;2021:1–12.
63. Harahap Y, Tamabri A, Vicha, Suryadi H, Sunarsih, Mulyadi CA. Pharmacokinetic study and incurred sample stability of esomeprazole in dried blood spot sample using high performance liquid chromatography-photodiode array. *Indones J Chem.* 2020;20(5):979–986.
64. Cortese M, Gigliobianco MR, Magnoni F, Censi R, Martino P Di. Molecules Compensate for or Minimize Matrix Effects ? Strategies for Overcoming Matrix Effects in Liquid. *Molecules.* 2020;25:3047.